Menu

Virus Like Particles

ALL Virus Like Particles

Filter By

Product Type

Product Category

Target Pathogen

Product Target

Application

Ebola Virus like particles (HA-EBOV) Sudan (Genebank: YP_138523.1)

Ebola Virus like particles (HA-EBOV) Sudan (Genebank: YP_138523.1) A novel rapid hybrid alpha-pseudovirus for Ebolaviruses (EBOV) (HA-EBOV) that are available for your initial testing from the Sudan Ebola strain (Genebank: YP_138523.1).  These pseudoviruses are BSL2 safe and ready to use for studying viral entry. HAEBOV particles are pseudoviruses assembled from the structural proteins of the filovirus glycoprotein (GP), VP40 matrix protein, and the Nucleoprotein (NP) and package an alphaviral vector for reporter gene expression. The alpha-pseudoviruses are single-cycle viruses with self-replicating RNA for rapid quantification of neutralizing antibodies and entry-inhibiting drugs. Size:
  • 1X concentrated 25 x 200 µL ~100 wells/96 well plate
Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Available upon request.  Store at -80°C. Applications
  • Rapid NiV pseudovirus transduction of target cells for viral entry and functional studies
  • Anti-NiV drug screening
  • Anti-NiV neutralizing antibody screening
Intended for research use only, not for human, therapeutic, or diagnostic applications.
  • Cat No:
  • 0571-PP-002
  • Product Type:
  • Virus like particles

Price:

$4,100.00

BUY NOW

Ebola Virus like particles (HA-EBOV) Zaire (Genebank: KJ660346.2)

Ebola Virus like particles (HA-EBOV) Zaire (Genebank: KJ660346.2) A novel rapid hybrid alpha-pseudovirus for Ebolaviruses (EBOV) (HA-EBOV) from the Zaire strain that are available for your initial testing.  These pseudoviruses are BSL2 safe and ready to use for studying viral entry. HAEBOV particles are pseudoviruses assembled from the structural proteins of the filovirus glycoprotein (GP), VP40 matrix protein, and the Nucleoprotein (NP) and package an alphaviral vector for reporter gene expression. The alpha-pseudoviruses are single-cycle viruses with self-replicating RNA for rapid quantification of neutralizing antibodies and entry-inhibiting drugs. Size:
  • 1X concentrated 25 x 200 µL ~100 wells/96 well plate
Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Available upon request.  Store at -80°C. Applications
  • Rapid NiV pseudovirus transduction of target cells for viral entry and functional studies
  • Anti-NiV drug screening
  • Anti-NiV neutralizing antibody screening
Intended for research use only, not for human, therapeutic, or diagnostic applications.
  • Cat No:
  • 0571-PP-001
  • Product Type:
  • Virus like particles

Price:

$4,100.00

BUY NOW

Ebola virus-like particles (EBOV VLP) (Zaire)

Virus-like Particles (VLP’s) expressing recombinant Ebola virus (EBOV) glycoprotein (GP), nucleoprotein (NP), and matrix protein (VP40). These VLP’s mimic Ebola virus but do not contain genetic material, thus are not infectious and make an ideal candidate as a vaccine and tool to enhance filovirus research.
  • Formulation & Storage: Supplied in PBS (supplemented with arginine and glutamic acid). Store at 2-3 weeks at -20°C, -80°C long term. Subaliquoting is recommended to avoid repeated freeze/thaw cycles.
  • Pathogen Strain: Zaire
  • Purification: Column chromatography
  • Expression: SF9 cells
  • Please note: After thawing, VLP’s tend to sediment to bottom of the tube and appear as aggregate pellet. Resuspend by gentle vortexing or pipetting up and down
  • Certificate of analysis: A hardcopy of datasheet is sent along with the products. Please refer to it for detailed information.
Please email products@integratedbiotherapeutics.com for lot specific information for ‘Titer’ and ‘Usage’.
  • Cat No:
  • 0550-001
  • Product Type:
  • Virus like particles

Price:

$689.00

BUY NOW

HIV Virus like particle (Human Immunodeficiency Virus)

HIV Virus like particle (VLP’s) expressing recombinant structural proteins Safe for use in BSL-2 facilities. Size:
  • 1X concentrated 25 x 200 µL ~100 wells/96 well plate
Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Available upon request.  Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.
  • Cat No:
  • 0572-PP-001
  • Product Type:
  • Virus like particles

Price:

$4,100.00

BUY NOW

Influenza H5 Pseudovirus

Lentivirus vector pseudotyped with Influenza H5 hemagglutinin. Lentiviral vectors are self-inactivating (SIN), and thus restrict mRNA production from integrating vectors to the internal promoter, severely reducing full-length vector transcripts. Infectivity and neutralization of infectivity can be measured by luciferase activity.
  • Formulation & Storage: Supplied in phosphate buffered saline (PBS). Store at -80°C, avoid freeze/thaw cycles.
  • Titer Estimate*: 2.2 x 105 RLU/µL
  • Usage Estimates*: Approximately 1 mL can be used to perform 2,,000 reactions or 20 x 96-well plates.
  • Reporter: Luciferase
Please email products@integratedbiotherapeutics.com for lot specific information for ‘Titer’ and ‘Usage’.
  • Cat No:
  • 1005-PP-005
  • Product Type:
  • Pseudovirus

Price:

$1,294.00

BUY NOW

Influenza H7 Pseudovirus

Lentivirus vector pseudotyped with Influenza H7 hemagglutinin. Lentiviral vectors are self-inactivating (SIN), and thus restrict mRNA production from integrating vectors to the internal promoter, severely reducing full-length vector transcripts. Infectivity and neutralization of infectivity can be measured by luciferase activity.
  • Formulation & Storage: Supplied in phosphate buffered saline (PBS). Store at -80°C, avoid freeze/thaw cycles.
  • Titer Estimate*: 2.2 x 105 RLU/µL
  • Usage Estimates*: Approximately 1 mL can be used to perform 2,,000 reactions or 20 x 96-well plates.
  • Reporter: Luciferase
Please email products@integratedbiotherapeutics.com for lot specific information for ‘Titer’ and ‘Usage’.
  • Cat No:
  • 1005-PP-007
  • Product Type:
  • Pseudovirus

Price:

$1,294.00

BUY NOW

Marburg virus like particles (HA-MARV) MARV001 Isolate (Genebank: OL702894.1)

Marburg virus like particles (HA-MARV) MARV001 Isolate (Genebank: OL702894.1) A novel rapid hybrid alpha-pseudovirus for Marburg (MARV) (HA-MARV) MARV001 Isolate that is available for your initial testing.  These pseudoviruses are BSL-2 safe and ready to use for studying viral entry. HA-MARV particles are pseudoviruses assembled from the structural proteins of the filovirus glycoprotein (GP), VP40 matrix protein, and the Nucleoprotein (NP) and package an alphaviral vector for reporter gene expression. The alpha-pseudoviruses are single-cycle viruses with self-replicating RNA for rapid quantification of neutralizing antibodies and entryinhibiting drugs. Size:
  • 1X concentrated 25 x 200 µL ~100 wells/96 well plate
Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Available upon request.  Store at -80°C. Applications
  • Marburg pseudovirus transduction of target cells for viral entry and functional studies
  • Rapid Anti-Marburg drug screening
  • Rapid Anti-Marburg neutralizing antibody
Intended for research use only, not for human, therapeutic, or diagnostic applications.
  • Cat No:
  • 0571-PP-003
  • Product Type:
  • Virus like particles

Price:

$4,100.00

BUY NOW

Marburg-Musoke virus-like particles (MMARV VLP)

Virus-like Particles (VLP’s) expressing recombinant Marburg (MARV) glycoprotein (GP), nucleoprotein (NP), and matrix protein (VP40). Since these VLP’s mimic MARV (Musoke) virus but do not contain genetic material, thus are not infectious making an ideal candidate as a vaccine and a tool to enhance filovirus research.
  • Formulation & Storage: Supplied in PBS (supplemented with arginine and glutamic acid). Store at 2-3 weeks at -20°C, -80°C long term. Subaliquoting is recommended to avoid repeated freeze/thaw cycles.
  • Pathogen Strain: Musoke
  • Purification: Column chromatography
  • Expression: SF9 cells
  • Please note: After thawing, VLP’s tend to sediment to the bottom of the tube and appear as aggregate pellet. VLP’s can be resuspended by gentle vortexing or by pipetting up and down, before use. Also, subaliquoting is recommended to avoid repeated freeze/thaw cycles.
  • Certificate of analysis: A hardcopy of datasheet is sent along with the products. Please refer to it for detailed information.
 
  • Cat No:
  • 0566-001
  • Product Type:
  • Virus like particles

Price:

$689.00

BUY NOW

Middle Eastern Respiratory Syndrome Corona Virus 2 (MERS-CoV-2) Virus Like Particle, Wild Type

Middle Eastern Respiratory Syndrome Corona Virus 2 (MERS-CoV-2) Virus Like Particle, Wild Type The hybrid alpha-pseudovirus for MERS-CoV-2 (Ha-MERSCoV-2) is a newly developed MARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)pseudoviruses, Ha-MERS-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of MERS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Size:
  • 60X concentrated 5 x 100 µL
  • 1x Conc. 25 x 200uL (~100 wells)
Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Applications:
  • Screening and quantification of anti-coronavirusneutralizing antibodies
  • Anti-coronavirus drug screening
  • Quantification of viral mutants’ infectivity
  • Identification of host co-factors and restriction factors of coronaviruses
Intended for research use only, not for human, therapeutic, or diagnostic applications.
  • Cat No:
  • 0569-PP-002
  • Product Type:
  • Virus like particles

Price:

$1,490.00 – $2,350.00

BUY NOW

Nipah Virus-like particles (HA-NiV)

Nipah Virus-like particles (HA-NiV) A novel rapid hybrid alpha-pseudovirus for Nipah virus (HA-NiV). HA-NiV particles are pseudoviruses assembled from the structural proteins of the Nipah virus, Fusion (F), Glycoprotein (G), Matrix (M), and Nucleocapsid (N) proteins and package an alphaviral vector for reporter gene expression. The alphapseudoviruses are single-cycle viruses with self-replicating RNA for rapid quantification of neutralizing antibodies and entry-inhibiting drugs. These pseudoviruses are BSL-2 safe and ready to use for studying viral entry. Size:
  • 1X concentrated 25 x 200 µL ~100 wells/96 well plate
Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Applications
  • Rapid NiV pseudovirus transduction of target cells for viral entry and functional studies
  • Anti-NiV drug screening
  • Anti-NiV neutralizing antibody screening
Intended for research use only, not for human, therapeutic, or diagnostic applications.
  • Cat No:
  • 0570-PP-001
  • Product Type:
  • Virus like particles

Price:

$4,100.00

BUY NOW

SARS-CoV-2 Virus Like Particles (Ha-CoV2) Delta Plus (AY.2)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) Delta Plus (AY.2) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike T19R, Spike V70F, Spiked del157/158, Spike A222V, Spike K417N, Spike L452R, Spike T478K, Spike D614G, Spike P681R, Spike D950N Size:
  • 25 X 200 µL ~100 wells/96 well plate
  • 60x Conc. 5 x 100 µL
Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.
  • Cat No:
  • 0568-PP-016
  • Product Type:
  • Virus like particles

Price:

$1,490.00 – $2,350.00

BUY NOW

SARS-CoV-2, Virus Like Particles (Alpha (B.1.1.7))

SARS-CoV-2 Virus Like Particles (Alpha (B.1.1.7)) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike mutations: Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike T716I, Spike V70del, Spike Y145del Size:
  • 25 X 200 µL ~100 wells/96 well plate
  • 60x Conc. 5 x 100 µL
Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Available upon request. Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.  
  • Cat No:
  • 0568-PP-003
  • Product Type:
  • Virus like particles

Price:

$1,490.00 – $2,350.00

BUY NOW

SARS-CoV-2, Virus Like Particles (B.1.1.207)

Virus Like Particles for SARS-CoV-2 strain: B.1.1.207 The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2, Virus Like Particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike mutations: Spike D614G, Spike E484K, Spike P681H Size:
  • 25 X 200 µL ~100 wells/96 well plate
  • 60x Conc. 5 x 100 µL
Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Available upon request. Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.
  • Cat No:
  • 0568-PP-004
  • Product Type:
  • Virus like particles

Price:

$1,490.00 – $2,350.00

BUY NOW

SARS-CoV-2, Virus Like Particles (D614G Single AA Mutant)

The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike mutations: Spike D614G Size(s):
  • 25 X 200 µL ~100 wells/96 well plate
  • 60x Conc. 5 x 100 µL
Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Available upon request. Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications
  • Cat No:
  • 0568-PP-002
  • Product Type:
  • Virus like particles

Price:

$1,490.00 – $2,350.00

BUY NOW

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.1.298)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.1.298) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike D614G, Spike H69del, Spike I692V, Spike M1229I, Spike V70del, Spike Y453F Size:
  • 25 X 200 µL ~100 wells/96 well plate
  • 60x Conc. 5 x 100 µL
Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.
  • Cat No:
  • 0568-PP-005
  • Product Type:
  • Virus like particles

Price:

$1,490.00 – $2,350.00

BUY NOW

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.2)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.2) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike D614G, Spike E484K, Spike G446V, Spike Y453F Size:
  • 25 X 200 µL ~100 wells/96 well plate
  • 60x Conc. 5 x 100 µL
Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.
  • Cat No:
  • 0568-PP-006
  • Product Type:
  • Virus like particles

Price:

$1,490.00 – $2,350.00

BUY NOW

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.258)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.258) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike D614G, Spike H69del, Spike N439K, Spike V70del Size:
  • 25 X 200 µL ~100 wells/96 well plate
  • 60x Conc. 5 x 100 µL
Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.
  • Cat No:
  • 0568-PP-007
  • Product Type:
  • Virus like particles

Price:

$1,490.00 – $2,350.00

BUY NOW

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.351)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.351) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike A243del, Spike A701V, Spike D80A, Spike D215G, Spike D614G, Spike E484K, Spike K417N, Spike L242del, Spike L244del, Spike N501Y Size:
  • 25 X 200 µL ~100 wells/96 well plate
  • 60x Conc. 5 x 100 µL
Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.
  • Cat No:
  • 0568-PP-008
  • Product Type:
  • Virus like particles

Price:

$1,490.00 – $2,350.00

BUY NOW

FEATURED PRODUCTS

Related products

Ebola virus-like particles (EBOV VLP): Western Blot was used to confirm the presence of EBOV-specific GP, NP and VP40 in the VLP. VLP sample was heat-denatured under reducing condition and loaded at 1 µg/lane. (A) GP was detected as a broadly-diffused band 60-110 kDa using 50 ng/mL of anti-EBOV GP rabbit Pab (cat# 0301-015) (B) NP was detected as a single sharp band at ~90 kDa using 100 ng/mL of anti-EBOV NP rabbit Pab (cat# 0301-012) (C) VP40 was detected as a single sharp band at ~40 kDa using 50 ng/mL of anti-EBOV VP40 rabbit Pab (cat# 0301-010)

Ebola virus-like particles (EBOV VLP) (Zaire)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) Kappa (B.1.617.1)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.494)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.1.298)

Viral Titration: Serially diluted pseudoviruses in EMEM™ in a 2-fold series were added to Vero cells seeded in a 96-well plate at a seeding density of 6E4 cells/well. Cells with media alone were used as control. After 24 h, the infection was monitored using the Luciferase Assay System (Promega, Madison, WI, USA). Viral titer was calculated using a dilution that resulted in a Relative Luciferase Unit (RLU). The RLU value recommended for this product is based readout from the BioTek Cytation™ instrument. Absolute RLU obtained by the user may vary based on the user’s instrument & handling or luciferase assay system.

rVSV-pseudotyped Ebola virus GP (rVSV-EBOV-GP)

Search
Generic filters